Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model

Cancer Prevention Research

Volumn 5, Issue 7, 2012, Pages 952-962

  Lin, Hsiu Ching ^a   Chen, Yi Fan ^c   Hsu, Wen Hsin ^a   Yang, Chu Wen ^b   Kao, Cheng Heng ^d   Tsai, Ting Fen ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b SOOCHOW UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GLUTATHIONE; HEPATITIS B VIRUS X PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; R 5010; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CELL ULTRASTRUCTURE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATITIS B VIRUS; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; MALE; MITOCHONDRIAL VOLUME DENSITY; MOUSE; NONHUMAN; PLEIOTROPY; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; DISEASE MODELS, ANIMAL; FATTY LIVER; GLUTATHIONE; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS, EXPERIMENTAL; LIVER REGENERATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 84866446123     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0001     Document Type: Article

References (42)

1. Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008;48:2047-63.
2. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127 Suppl 1:S5-16.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76. (Pubitemid 46890874)
4. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
5. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32.
6. Tessari P, Coracina A, Cosma A, Tiengo A. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2009;19:291-302.
7. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506. (Pubitemid 44136961)
8. Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta 2011;1812:1477-89.
9. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, Gharbi N, Kamoun A, et al. Protective effect of resveratrol on ethanol-induced lipid peroxidation in rats. Alcohol Alcohol 2006;41:236-9.
10. Kasdallah-Grissa A, Mornagui B, Aouani E, Hammami M, El May M, Gharbi N, et al. Resveratrol, a red wine polyphenol, attenuates ethanol-induced oxidative stress in rat liver. Life Sci 2007;80:1033-9. (Pubitemid 46204723)
11. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2008;295:G833-42.
12. Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, García-Urkia N, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol 2008;8:40.
13. Bishayee A, Politis T, Darvesh AS. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat Rev 2010;36:43-53.
14. Bishayee A, Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. ChemBiol Interact 2009;179:131-44.
15. Bishayee A, Barnes KF, Bhatia D, Darvesh AS, Carroll RT. Resveratrol suppresses oxidative stress and inflammatory response in diethylni-trosamine- initiated rat hepatocarcinogenesis. Cancer Prev Res 2010;3:753-63.
16. Mbimba T, Awale P, Bhatia D, Geldenhuys WJ, Darvesh AS, Carroll RT, et al. Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr Pharm Biotechnol 2012;13:229-34.
17. Wu BK, Li CC, Chen HJ, Chang JL, Jeng KS, Chou CK, et al. Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice. Biochem Biophys Res Commun 2006;340:916-28.
18. Wu YF, Fu SL, Kao CH, Yang CW, Lin CH, Hsu MT, et al. Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice. Cancer Res 2008;68:2033-42. (Pubitemid 351416591)
19. Young B, Heath JW. WHEATER'S functional histology: a text and colour atlas. 4th ed. Philadelphia: Churchill Livingstone; 2000.
20. Kao CH, Chen JK, Kuo JS, Yang VC. Visualization of the transport pathways of low density lipoproteins across the endothelial cells in the branched regions of rat arteries. Atherosclerosis 1995;116:27-41.
21. Papeleu P, Vanhaecke T, Henkens T, Elaut G, Vinken M, Snykers S, et al. Isolation of rat hepatocytes. Methods Mol Biol 2006;320:229-37.
22. Sambrook J, Russell DW. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2001.
23. Harlow E, Lane D. Using antibodies: a laboratory manual. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 1999.
24. Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, et al. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One 2011;6:e19881.
25. Weibel ER. Stereological techniques for electron microscope. In: Hayat MA, editor. Principles and techniques of electron microscope, biological applications. New York: Van Nostrand-Reinhold; 1973. p. 237.
26. Kim KH, Shin HJ, Kim K, Choi HM, Rhee SH, Moon HB, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology 2007;132:1955-67. (Pubitemid 46677949)
27. Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRalpha. Biochem J 2008;416:219-30.
28. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31. (Pubitemid 34496588)
29. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 2003;278:34268-76. (Pubitemid 37553270)
30. Yu S, Matsusue K, Kashireddy P, Cao WQ, Yeldandi V, Yeldandi AV, et al. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J Biol Chem 2003;278:498-505. (Pubitemid 36043602)
31. Na TY, Shin YK, Roh KJ, Kang SA, Hong I, Oh SJ, et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009;49:1122-31.
32. Lee YI, Kang-Park S, Do SI, Lee YI. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem 2001;276:16969-77.
33. Kohjima M, Higuchi N, Kato M, Kotoh K, Yoshimoto T, Fujino T, et al. SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease. Int J Mol Med 2008;21:507-11. (Pubitemid 351802646)
34. Yuan H, Shyy JY, Martins-Green M. Second-hand smoke stimulates lipid accumulation in the liver by modulating AMPK and SREBP-1. J Hepatol 2009;51:535-47.
35. Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 2010;1804:1626-34.
36. Kirimlioglu V, Karakayali H, Turkoglu S, Haberal M. Effect of resveratrol on oxidative stress enzymes in rats subjected to 70% partial hepatectomy. Transplant Proc 2008;40:293-6. (Pubitemid 351186622)
37. Rivera H, Shibayama M, Tsutsumi V, Perez-Alvarez V, Muriel P. Resveratrol and trimethylated resveratrol protect from acute liver damage induced by CCl4 in the rat. J Appl Toxicol 2008;28:147-55. (Pubitemid 351428287)
38. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008;135:111-21.
39. Juan ME, Vinardell MP, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002;132:257-60. (Pubitemid 34135604)
40. Hebbar V, Shen G, Hu R, Kim BR, Chen C, Korytko PJ, et al. Toxicogenomics of resveratrol in rat liver. Life Sci 2005;76:2299-314. (Pubitemid 40313418)
41. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J. Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 2009;47:2170-82.
42. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS Resveratrol-associated renal toxicity. Toxicol Sci 2004;82:614-9. (Pubitemid 39600090)